Research Report Details
Subscribe for industry reports
Author / Researcher : Global Business Intelligence Research
Number Of Pages/Tabs : 79
Number Of Charts : N/A
Published Date : 02/16/2016
Industries : Multiple
Countries : All
Quality Score : 5
Have a question about this report?
24/7 Research Support
Talk to Zursh Analyst
+1 858 522 9998 or Email Us
The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape.
The degree and proportion of breakthrough innovations in this pipeline is exceptional – GBI Research analysis identified 333 first-in-class programs in the breast cancer pipeline, acting on 251 first-in-class molecular targets.
This accounts for some 39% of all products with a disclosed molecular target, and is reflective of the high degree of innovation in this indication.
This has far-reaching strategic implications for all market participants, as despite the high attrition rate in breast cancer, it is highly likely many of the first-in-class products will reach the market over the coming decade and, will have the opportunity to transform the clinical and commercial landscape. Potential driving factors behind this market include a very large and growing patient pool, a well-established disease market with a number of strong unmet needs, and the strong understanding of the disease pathophysiology that has developed over the last decade, facilitating the development of novel compounds that may fill the unmet needs. Some 289 first-in-class products that are currently in development have not yet been involved in licensing or co-development deals, meaning there are numerous opportunities for in-licensing or co-development in this indication, which already has a strong track record of breakthrough innovation yielding highly commercially and clinically successful therapies. Scope - The report analyzes innovation in breast cancer, in the context of the overall pipeline and current market landscape.
In addition, it analyzes the deals landscape surrounding first-in-class products in breast cancer, and pinpoints opportunities for in-licensing. - A brief introduction to breast cancer, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms. - The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline. - Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target. - Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets. - Assessment of the licensing and co-development deal landscape for breast cancer therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products. Reasons to buy - Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis. - Visualize the composition of the breast cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed.
This knowledge allows a competitive understanding of the gaps in the current market. - Analyze the breast cancer pipeline, stratified by stage of development, molecule type and molecular target. - Assess the therapeutic potential of first-in-class targets.
Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential.
Promising early-stage targets have been further reviewed in greater detail. - Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals, and producing a list of breast cancer therapies that are not yet involved in deals and may be potential investment opportunities.
1 Table of Contents 1 Table of Contents 2 1.1 List of Tables 3 1.2 List of Figures 3 2 Executive Summary 4 2.1 Exceptionally Large and Innovative Pipeline 4 2.2 Alignment of First-in-Class Molecular Target with Disease Causation 4 2.3 Highly Active Deals Landscape with Numerous Investment Opportunities 4 3 The Case for Innovation in the Breast Cancer Market 5 3.1 Growing Opportunities for Biologic Products 5 3.2 Diversification of Molecular Targets 5 3.3 Innovative First-in-Class Product Developments Remain Attractive 5 3.4 Changes in Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Indications 5 3.5 Sustained Innovation 6 3.6 Report Guidance 6 4 Clinical and Commercial Landscape 8 4.1 Disease Overview 8 4.2 Epidemiology 8 4.3 Disease Symptoms 9 4.4 Etiology 9 4.4.1 Age and Gender 9 4.4.2 Genetic Makeup 9 4.4.3 Environmental 10 4.5 Pathophysiology 10 4.5.1 Tumor Initiation and Aberrant Cell Proliferation and Survival 10 4.5.2 Tumor Metabolic Shift 11 4.5.3 Tumor Progression, Micro-environment Alteration and Angiogenesis 12 4.5.4 Cancer Stem Cells 13 4.6 Diagnosis 13 4.7 Prognosis and Disease Staging 14 4.7.1 Classification 15 4.8 Introduction to Breast Cancer Treatments 16 4.9 Surgery and Radiation Therapy 17 4.10 Overview of Marketed Products for Breast Cancer 17 4.10.1 Chemotherapy 18 4.10.2 Hormonal Therapies 19 4.10.3 Targeted Therapies 19 4.11 Treatment Algorithm 21 4.12 Current Unmet Need in Breast Cancer Market 23 5 Assessment of Pipeline Product Innovation 25 5.1 Breast Cancer Pipeline by Phase, Molecule Type and Molecular Target 25 5.2 First-in-Class Pipeline Programs 29 6 Signaling Network, Disease Causation and Innovation Alignment 36 6.1 The Complexity of Signaling Networks in Oncology 36 6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 37 6.3 First-in-Class Target Matrix Assessment 37 7 First-in-Class Target Evaluation 41 7.1 Pipeline Programs which Target FGFR 3 and 4 41 7.2 Pipeline Programs which Target HER3 42 7.3 Pipeline Programs which Target PDK1 44 7.4 Pipeline Programs which Target Akt 1, 2 and 3 45 7.5 Pipeline Programs which Target PI3K-alpha 48 7.6 Conclusion 50 8 Deals and Strategic Consolidations 51 8.1 Industry-Wide First-in-Class Deals 51 8.2 Breast Cancer Deals Landscape 52 8.3 Licensing Deals 53 8.3.1 Molecule Type 55 8.3.2 Molecular Target 56 8.4 Co-development Deals 59 8.4.1 Molecule Type 60 8.4.2 Molecular Target 61 8.5 First-In-Class Molecules not Involved in Licensing or Co-development Deals 63 9 Appendix 66 9.1 Abbreviations 66 9.2 References 66 9.3 Contact Us 79 9.4 Disclaimer 79 1.1 List of Tables Table 1: Tumor, regional lymph Node and Metastasis Staging, 2010–2013 14 Table 2: US, Disease Stage at Diagnosis and Five-year Relative Survival (%), 2013 14 Table 3: Breast Cancer Histopathological and Molecular Classification 15 Table 4: Key Features and Pipeline Activity of FGFR3 41 Table 5: Key Features and Pipeline Activity of FGFR4 42 Table 6: Pipeline Programs Targeting FGFR4 42 Table 7: Key Features and Pipeline Activity of HER3 43 Table 8: Key Features and Pipeline Activity of PDPK1 44 Table 9: Key Features and Pipeline Activity of Akt1 46 Table 10: Key Features and Pipeline Activity of Akt2 46 Table 11: Key Features and Pipeline Activity of Akt3 47 Table 12: Key Features and Pipeline Activity of PI3K-alpha 48
Summary of Source & MethodologyTrue
Global Business Intelligence, as part of GlobalData, follows the highest standards when conducting primary and secondary research, including thousands of interviews with senior executives every year, to enable clients to make sound business decisions for their company in complete confidence. 1. 1 million-strong stakeholder group, plus 25,000 interviews annually 2. Rigorous checks on over 25,000 public and proprietary sources 3. Data modeled and forecasted with gold-standard methodology 4. Updated in real time 5. Expert insights and critical analysis from 700 experienced researchers and analysts If you would like to request the complete research methodology of this report or any additional information, please send us an email to email@example.com
Download additional documents & original sources used by researcher/publisher to support the report dataDownload Documents No documents available for download
Zursh quality control analysts have developed a nice rating algorithm to independently and objectively evaluate the quality of this report.